L-arginine,
does it really help with Improvement of mild to moderate erectile dysfunction?
research showsL-arginine monotherapy may improve mild to moderate erectile dysfunction, but the evidence is graded C. The 10 trials with 540 participants cannot all be treated as monotherapy evidence. In the improvement-rate analysis, monotherapy produced OR 3.37 across three trials with 175 participants, whereas combination products produced OR 18.93 across three trials with 134 participants, concentrating the large effect in combinations. A later 98-participant monotherapy product trial improved IIEF-6 and blood flow in mild to moderate disease, but blood flow was null in severe disease. It is not equivalent to prescription PDE5 inhibitors, and evidence for severe erectile dysfunction is weak.
ads claimKorean products are marketed with phrases such as 'male vitality,' 'increased blood flow,' 'NO booster,' and 'natural erectile support,' and 5,000 mg sticks and liquids are common. A nitric-oxide mechanism does not guarantee clinical benefit, and combination-product findings cannot be assigned to L-arginine alone.
Useful facts when choosing a product
- Korean online distribution includes 500 mg capsules, 1,000 mg tablets, and 5,000 mg sticks or liquids, with substantial variation in formulation and content.
- The 2019 meta-analysis used 1.5 to 5 g/day, while a later monotherapy trial used 6 g/day for three months.
- Some Korean products advertised as 5,000 mg products also contain lysine, ornithine, carnitine, or zinc, so total product weight must be distinguished from pure L-arginine content.
- Oral L-arginine can cause gastrointestinal discomfort, diarrhea, and lower blood pressure. Concomitant use with nitrates, antihypertensives, or PDE5 inhibitors may increase hypotension risk.
What the research actually shows
The 2019 meta-analysis by Rhim and colleagues pooled 10 randomized trials with 540 participants but separated monotherapy from combinations in the improvement-rate analysis. L-arginine alone yielded OR 3.37 (95% CI 1.29 to 8.77) across three trials with 175 participants, while arginine combinations yielded OR 18.93 (1.69 to 212.21) across three trials with 134 participants, so the large effect cannot be assigned to L-arginine alone. The 2022 multicenter double-blind trial by Menafra and colleagues gave the branded monotherapy product Bioarginina at 6 g/day for three months to 98 men with vasculogenic erectile dysfunction. IIEF-6 and Doppler peak systolic velocity improved overall and in mild to moderate disease, but peak systolic velocity did not improve in severe disease, and normalization was concentrated mainly among participants with mild disease at baseline.
Why this is classified as C (58)
Monotherapy has positive signals from three improvement-rate trials with 175 participants and a later 98-participant trial, but samples are small, subjective measures predominate, and the later study used a branded product. The large pooled effect was concentrated in combination products whose ingredient contributions cannot be isolated, and the objective blood-flow result was null in severe disease. Under the category 2-b/category 1 ceiling, this limited replicated signal supports C with 58 points.
Counterpoint. An adjunctive benefit remains plausible in mild to moderate, particularly vasculogenic, erectile dysfunction. This verdict concerns a different erectile-function axis from the fatigue and vitality claim in item 39 and does not extend to severe disease, every cause, equivalence to PDE5 inhibitors, or replacement of prescription treatment.
Rejudgment record. Reassessment (cross-check reflected) — Applied the category 2-b/category 1 ceiling, separating the limited positive signal from three monotherapy trials with 175 participants from the much larger effect in three combination-product trials with 134 participants, while incorporating subjective benefits and the null severe-disease objective blood-flow result from the later branded monotherapy trial
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Improvement of mild to moderate erectile dysfunction with arginine alone | C | Three monotherapy trials with 175 participants were positive, but they were small, and the later trial was limited by a branded product and subjective measures. |
| Combination products or severe erectile dysfunction | D | Combination products do not isolate the contribution of arginine alone, and objective blood-flow improvement was null in severe disease. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Rhim HC et al. 2019 | Systematic review and meta-analysis | 134 | No conflict reported for the review; funding varied across included trials | Improvement response, IIEF, intercourse satisfaction, and orgasmic function | For improvement rate, L-arginine alone yielded OR 3.37 (95% CI 1.29 to 8.77), whereas combination products yielded OR 18.93 (1.69 to 212.21), concentrating the large effect in combinations. | Key |
| Chen J et al. 1999 | Double-blind randomized placebo-controlled trial | 50 | Unknown | Sexual-function questionnaire, sexual-activity diary, and nitric oxide | This small monotherapy trial tested L-arginine 5 g/day for six weeks and found a response signal, but the sample and instruments were limited. | Supportive |
| Menafra D et al. 2022 | Multicenter double-blind randomized placebo-controlled trial | 95 | Study product supplied by Farmaceutici Damor; authors reported no conflicts | IIEF-6 and penile peak systolic velocity | After Bioarginina at 6 g/day for three months, IIEF-6 and blood-flow velocity improved overall and in mild to moderate disease, but only IIEF-6 improved and blood-flow velocity was null in severe disease. | Key |
Receipt — 4 References
All 4 cited sources were verified for existence at the original page (as of 2026-07-18).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-18 · Corrections: none
Cite this verdict
[Chamgap] L-arginine x mild to moderate erectile dysfunction — Evidence Grade C·58. 4 cited sources checked. Source: https://chamgap.com/en/verdicts/mens/l-arginine-erectile-dysfunction/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.